HIF-1 Alpha Overexpression Correlates with Poor Overall Survival and Disease-Free Survival in Gastric Cancer Patients Post-Gastrectomy

Background Overall, gastric cancer prognosis remains poor. Detailed characterization of molecular markers that govern gastric cancer pathogenesis is warranted to establish innovative therapeutic options. HIF-1α overexpression has been linked to poor gastric cancer prognosis. However, though researched for years, the prognostic role of HIF-1α in gastric cancer is still controversial. Hence, the objective of the present study was to analyze the prognostic values of HIF-1α, TGF-β, VEGF and pERK1/2 in gastric cancer patients following gastrectomy. Methods This study included 446 patients with confirmed gastric cancer who underwent gastrectomy in a single Chinese Cancer Center between 2005 and 2006. Clinicopathologic features, as well as immunohistochemical analysis of TGF-β, HIF-1α, VEGF and pERK1/2 were determined. Long-term survival of these patients was analyzed using univariate and multivariate analyses. Results HIF-1α overexpression was more frequent in patients with hepatic metastases (71.6% versus 43.0% in those without hepatic metastases, P = 0.000, χ2 = 23.086) and more frequent in patients with peritoneum cavity metastasis (62.3% versus 43.0% in those without such metastasis, P = 0.000, χ2 = 13.691). In univariate analysis, patients with HIF-1α overexpression had a shorter disease-free survival (DFS) and overall survival (OS) than patients with weak-expression (DFS: NA VS. 16.8 m, P = 0.000, χ2 = 74.937; OS: NA VS. 25.5 m, P = 0.000, χ2 = 90.594). Importantly, HIF-1α overexpression was a promising prognostic marker for poor survival by multivariate analysis (DFS: HR 2.766, 95%CI 2.136–2.583, P = 0.000; OS: HR 3.529, 95%CI 2.663–4.667, P = 0.000). Conclusions HIF-1α overexpression could be considered a useful independent prognostic biomarker in gastric cancer after gastrectomy, and is correlated to both a poor overall survival and disease-free survival in these patients. HIF-1α expression can be used to stratify patients at higher risk for poor prognosis, and is potentially an important therapeutic target in gastric cancer patients.

[1]  S. Natsugoe,et al.  Hypoxia inducible factor‐1 alpha plays a pivotal role in hepatic metastasis of pancreatic cancer: an immunohistochemical study , 2014, Journal of hepato-biliary-pancreatic sciences.

[2]  K. Yanagihara,et al.  HIF-1α is a crucial factor in the development of peritoneal dissemination via natural metastatic routes in scirrhous gastric cancer. , 2013, International journal of oncology.

[3]  Qian Zhang,et al.  Hypoxia-Inducible Factor-1α Polymorphisms and Risk of Cancer Metastasis: A Meta-Analysis , 2013, PloS one.

[4]  Q. Wei,et al.  TGFβ1 Polymorphisms Predict Distant Metastasis–Free Survival in Patients with Inoperable Non-Small-Cell Lung Cancer after Definitive Radiotherapy , 2013, PloS one.

[5]  Hua-mei Tang,et al.  Overexpression of RBBP6, Alone or Combined with Mutant TP53, Is Predictive of Poor Prognosis in Colon Cancer , 2013, PloS one.

[6]  M. Okajima,et al.  Overexpression of Hypoxia Inducible Factor-1 Alpha is an Independent Risk Factor for Recurrence After Curative Resection of Colorectal Liver Metastases , 2013, Annals of Surgical Oncology.

[7]  L. Miele,et al.  EGCG, a major green tea catechin suppresses breast tumor angiogenesis and growth via inhibiting the activation of HIF-1α and NFκB, and VEGF expression , 2013, Vascular cell.

[8]  Xiyong Liu,et al.  Effects of the silencing of hypoxia-inducible Factor-1 alpha on metastasis of pancreatic cancer. , 2013, European review for medical and pharmacological sciences.

[9]  Lili Ma,et al.  Transforming Growth Factor-β1 and -β2 in Gastric Precancer and Cancer and Roles in Tumor-Cell Interactions with Peripheral Blood Mononuclear Cells In Vitro , 2013, PloS one.

[10]  Kou-Juey Wu,et al.  Hypoxia-regulated target genes implicated in tumor metastasis , 2012, Journal of Biomedical Science.

[11]  P. Jung,et al.  Dependency of colorectal cancer on a TGF-β-driven program in stromal cells for metastasis initiation. , 2012, Cancer cell.

[12]  R. Matkowski,et al.  HER-2 Expression in Immunohistochemistry Has No Prognostic Significance in Gastric Cancer Patients , 2012, TheScientificWorldJournal.

[13]  G. Semenza.  Hypoxia-inducible factors: mediators of cancer progression and targets for cancer therapy. , 2012, Trends in pharmacological sciences.

[14]  W. H. Kim,et al.  A hypoxia-dependent upregulation of hypoxia-inducible factor-1 by nuclear factor-κB promotes gastric tumour growth and angiogenesis , 2010, British Journal of Cancer.

[15]  W. Wong,et al.  Hypoxia-inducible factors and the response to hypoxic stress. , 2010, Molecular cell.

[16]  Xin Lu,et al.  Hypoxia and Hypoxia-Inducible Factors: Master Regulators of Metastasis , 2010, Clinical Cancer Research.

[17]  Bo Zhang,et al.  HIF-1α and HIF-2α correlate with migration and invasion in gastric cancer , 2010, Cancer biology & therapy.

[18]  M. Bertagnolli,et al.  Molecular origins of cancer: Molecular basis of colorectal cancer. , 2009, The New England journal of medicine.

[19]  Y. Liu,et al.  TGF-beta promotes invasion and metastasis of gastric cancer cells by increasing fascin1 expression via ERK and JNK signal pathways. , 2009, Acta biochimica et biophysica Sinica.

[20]  J. Pollard,et al.  Vascular endothelial growth factor restores delayed tumor progression in tumors depleted of macrophages , 2007, Molecular oncology.

[21]  P. Wooley,et al.  High VEGF with Rapid Growth and Early Metastasis in a Mouse Osteosarcoma Model , 2007, Sarcoma.

[22]  K. Miyazono,et al.  Ki26894, a novel transforming growth factor‐β type I receptor kinase inhibitor, inhibits in vitro invasion and in vivo bone metastasis of a human breast cancer cell line , 2007, Cancer science.

[23]  H. Munshi,et al.  Extracellular matrix-mediated membrane-type 1 matrix metalloproteinase expression in pancreatic ductal cells is regulated by transforming growth factor-beta1. , 2006, Cancer research.

[24]  Xiu-fen Lei,et al.  Inhibition of pulmonary and skeletal metastasis by a transforming growth factor-beta type I receptor kinase inhibitor. , 2006, Cancer research.

[25]  Farin Kamangar,et al.  Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  G. Hoser,et al.  Elevated TGF-β1 concentration in bronchoalveolar lavage fluid from patients with primary lung cancer , 2006, Archivum Immunologiae et Therapiae Experimentalis.

[27]  L. Ellis,et al.  Role of hypoxia-inducible factor 1alpha in gastric cancer cell growth, angiogenesis, and vessel maturation. , 2004, Journal of the National Cancer Institute.

[28]  H. Kato,et al.  Significance of expression of TGF-beta in pulmonary metastasis in non-small cell lung cancer tissues. , 2003, Annals of thoracic and cardiovascular surgery : official journal of the Association of Thoracic and Cardiovascular Surgeons of Asia.

[29]  Jinho Kim,et al.  YC-1: a potential anticancer drug targeting hypoxia-inducible factor 1. , 2003, Journal of the National Cancer Institute.

[30]  J. Folkman.  Role of angiogenesis in tumor growth and metastasis. , 2002, Seminars in oncology.

[31]  R. Bicknell,et al.  Hypoxia and oxidative stress in breast cancer: Oxidative stress: its effects on the growth, metastatic potential and response to therapy of breast cancer , 2001, Breast Cancer Research.

[32]  S. Tsujitani,et al.  An elevated serum level of transforming growth factor-beta 1 (TGF-beta 1) significantly correlated with lymph node metastasis and poor prognosis in patients with gastric carcinoma. , 2000, Anticancer research.

[33]  K. Flanders,et al.  Altered expression of transforming growth factor‐β1 in cervical neoplasia as an early biomarker in carcinogenesis of the uterine cervix , 1996, Cancer.

[34]  A. Melman,et al.  Elevated plasma levels of TGF-β1 in patients with invasive prostate cancer , 1995, Nature Medicine.

[35]  W. Remmele,et al.  [Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue]. , 1987, Der Pathologe.

[36]  S. Papson,et al.  “Model” , 1981 .

[37]  J. Folkman,et al.  Proceedings: Tumor angiogenesis factor. , 1974, Cancer research.

[38]  三宅 修輔.  HIF-1α is a crucial factor in the development of peritoneal dissemination via natural metastatic routes in scirrhous gastric cancer , 2014 .

[39]  Jin-Hui Tian,et al.  Hypoxia-inducible factor 1 alpha (HIF-1α) as a prognostic indicator in patients with gastric tumors: a meta-analysis. , 2013, Asian Pacific journal of cancer prevention : APJCP.

[40]  A. Jemal,et al.  Global Cancer Statistics , 2011 .

[41]  G. Hoser,et al.  Elevated TGF-beta1 concentration in bronchoalveolar lavage fluid from patients with primary lung cancer. , 2006, Archivum immunologiae et therapiae experimentalis.

[42]  Y. Maehara,et al.  Role of transforming growth factor-beta 1 in invasion and metastasis in gastric carcinoma. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[43]  A. Melman,et al.  Elevated plasma levels of TGF-beta 1 in patients with invasive prostate cancer. , 1995, Nature medicine.